Atossa’s Microcatheter Technology Is Being Enlisted By Leading Researchers In Upcoming Breast Cancer Study
The American Cancer Society (ACS) estimates that approximately 250,000 women will be diagnosed with breast cancer in the United States this year and that approximately 40,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that the lifetime risk of men getting breast cancer is about 1 in 1,000; 2,470 new cases of invasive breast cancer will be diagnosed; and 460 men will die from breast cancer in 2017. Annually in October, it is Breast Cancer Awareness Month!
This week, Atossa Genetics (NasdaqCM: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that the Ernest Mario School of Pharmacy at Rutgers, The State University at New Jersey, plans to conduct a study utilizing Atossa’s intraductal microcatheter technology.
The Rutgers researchers believe that directly administering drugs into the breast duct where breast cancer grows, by inserting microcatheters into the nipple, is a better alternative than systemic administration, because the drugs will be directly delivered to the tissue. The Rutgers program uses a unique directed delivery system comprised of nanoscale pharmaceutical carriers loaded with single drugs. The long-term goal of the research program is to develop a locally administered drug delivery system that selectively targets and delivers pathway-specific targeting therapeutics to eliminate breast cancer cells and cancer stem-like cells while sparing normal breast cells. The Rutgers program is in the research and development phase and has not been approved by the FDA or any other regulatory body. Studies demonstrating safety and efficacy, among other things, and regulatory approvals will be required before commercialization.
Steven Quay, MD, PhD, Atossa CEO and President stated, “We are encouraged that a leading research institution like Rutgers recognizes the potential merit of our microcatheter technology. Atossa fully supports additional research utilizing our patented microcatheter technology.”
To learn more about Atossa Genetics (NasdaqCM: ATOS) and to track their progress please visit the Vista Partners Company Dedicated Coverage Page.
Interested in healthcare? Please learn more about short-term alternative health insurance firm Health Insurance Innovations (NasdaqGM: HIIQ) & pharmaceutical and biotech giant Merck (NYSE: MRK) at Vista Partners Coverage Pages.